The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge

 
• By Sarah Karlin-Smith
  
dark forest with fallen tree
If a dozen Humira biosimilars launch, but formulary design doesn’t incentivize uptake, does the biosimilar pathway take a bow? • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics